A Cold Virus Wants to Treat Your Colon Cancer

First sites should activate later this month, with preliminary data expected by the end of 2026.

The Numbers That Got Us Here

The reason Oncolytics earned the right to run a randomized trial is a prior study called REO 022, and the results were striking.

In second-line KRAS-mutant MSS colorectal cancer, the pelareorep combination produced a 33% response rate. For context, the standard-of-care benchmark in this setting is roughly 6 to 11%. That's not a modest improvement; it's a tripling.

Survival data told an even more compelling story. Median progression-free survival hit 16.6 months versus 5.7 months for standard therapy. Median overall survival reached 27 months, compared to a historical benchmark of just 11.2 months. Those are the kinds of numbers that make oncologists sit up straight.

The FDA noticed too, granting pelareorep Fast Track Designation for this exact indication in early 2026.

The MSS Problem Nobody Has Solved

To understand why this matters, you need to know about the great divide in colorectal cancer. About 5% of metastatic CRC patients have tumors that are microsatellite instable (MSI-high), meaning they carry tons of mutations that make them visible to the immune system. Checkpoint inhibitors work beautifully for these patients.

The other 95%? Their tumors are microsatellite stable. They're essentially invisible to immunotherapy, wrapped in an immunosuppressive microenvironment that keeps T cells locked out. For these patients, treatment options after first-line chemo are bleak. Drugs like regorafenib offer a median survival of about 7 months.

The only recent bright spot came from the STELLAR-303 trial, where zanzalintinib plus atezolizumab nudged overall survival to 10.9 months versus 9.4 months for regorafenib. Meaningful, sure, but hardly transformative. If pelareorep's earlier numbers hold in a randomized setting, the gap would be enormous.

Not Just a One-Trick Virus

Colorectal cancer isn't pelareorep's only rodeo. The virus has shown intriguing results across multiple tumor types, which helps validate the underlying biology.

In HR-positive, HER2-negative metastatic breast cancer, the BRACELET-1 trial showed median progression-free survival nearly doubling from 6.4 to 12.1 months when pelareorep was added to paclitaxel. In first-line pancreatic cancer, pooled data from over 100 patients showed a two-year survival rate of 21.9%, compared to 9.2% historically.

The safety profile across more than 1,100 patients has been reassuringly boring: mostly transient flu-like symptoms (fever, chills, fatigue) with rare serious adverse events. For a therapy that's literally infecting you with a virus, that's a pretty manageable trade-off.

The Investor View

ONCY stock has been on a quiet climb, up about 26% year-to-date to roughly $1.10. Analyst price targets range from $1.37 to $4.26, with an average around $2.82, implying about 149% upside. The company's market cap sits at approximately $110 million, making it a micro-cap that could move dramatically on data readouts.

The stock's 52-week range tells the story of a volatile ride: a low of $0.33 and a high of $1.51. REO 033 data by year-end could determine which end of that range the stock is heading toward next.

What to Watch

The big question isn't whether pelareorep works in a petri dish or a small study. It's whether it works when you add a control group and remove the optimism bias. Randomized data is the truth serum of clinical trials.

With about 30 patients per arm, this study is powered for statistical significance on response rate, but it's still a Phase 2. Positive results would likely set the stage for a larger registrational trial rather than an immediate approval. The company is also planning an FDA meeting in mid-April to discuss a registrational study in anal cancer, another indication where pelareorep has shown a 29% response rate.

For now, the thesis is simple: if a humble cold virus can wake up the immune system in cancers that checkpoint inhibitors can't touch, it would fill one of the biggest unmet needs in oncology. Preliminary data by late 2026 will start to tell us if that thesis holds up under pressure.